NightWatch+

Take control of epilepsy at night

NightWatch+

NightWatch+

NightWatch+ detects and notifies caregivers of nocturnal epileptic motor seizures that are associated with a risk of injuries, including SUDEP (Sudden Unexpected Death in Epilepsy).

Wearable sensor that detects seizures using Photoplethysmography (PPG) and Accelerometry (ACC) sensors

Alarm station that instantly notifies caregivers about a seizure

NightWatch Portal to track seizure frequency over time

Thousands of caregivers trust on NightWatch every night

★★★★½
421 reviews
March, 2025

Nocturnal seizures are seizures during sleep. Motor seizures are epileptic seizures involving muscles in any way, which can be sudden stiffness, jerking of the muscles, or leg pedaling movements. NightWatch+ detects the following seizure types:

- Tonic-clonic
- Tonic (if clustered or prolonged)
- Hyperkinetic
- Myoclonic (if clustered)

NightWatch has been validated in multiple prospective clinical trials, demonstrating high sensitivity in detecting nocturnal seizures in adults and children living in residential and home settings. It reduces caregiver stress.

Epilepsia®

Published: May 17, 2023

Multimodal nocturnal seizure detection in children with epilepsy: A prospective, multicenter, long-term, in-home trial.

Anouk van Westrhenen, Richard H. C. Lazeron, Johannes P. van Dijk, Frans S. S. Leijten, Roland D. Thijs, the Dutch Tele-Epilepsy Consortium

- 51 children aged 4-16 at home, 2310 nights, 552 major nocturnal epileptic motor seizures
- Overall sensitivity of 94% for tonic-clonic seizures and 91% for other major motor seizures
- Median false alarm rate 0.04/h
- Significantly lower caregiver stress scores during NightWatch use

seizure

Published: August 16, 2022

An economic evaluation of the NightWatch for children with refractory epilepsy: Insight into the cost-effectiveness and cost-utility.

Anouk Engelgeer, Anouk van Westrhenen, Roland D. Thijs, Silvia M. A. A. Evers

- 41 Dutch families used NightWatch for two months
- Two months of NightWatch implementation showed a decrease in mean costs of €775
- Cost-effectiveness probability was 72% for NightWatch at a €50,000 cost-effectiveness threshold

Neurology®

Published: October 24, 2018

Multimodal nocturnal seizure detection in a residential care setting. A long-term prospective trial.

Johan Arends, Roland D. Thijs, Thea Gutter, Constantin Ungureanu, Pierre Cluitmans, Johannes van Dijk, Judith van Andel, Francis Tan, Al de Weerd, Ben Vledder, Wytske Hofstra, Richard Lazeron, Ghislaine van Thiel, Kit C. B. Roes, Frans Leijten and the Dutch Tele-Epilepsy Consortium

- 28 adults aged 15-67, 1826 nights, 809 major motor seizures
- Median sensitivity of 96% for tonic-clonic seizures and a median of 86% for major motor seizures
- Positive Predictive Value (PPV): 49%

Trial NightWatch+

Go to our website and order your
NightWatch+ with a 30-day trial period.
www.nightwatchepilepsy.com

LivAssured B.V.
Schipholweg 103
2316 XC Leiden
The Netherlands

Phone: +31 (0)850 601 252
Email: info@nightwatchepilepsy.com

	Sensor	Alarm station
Weight	35 grams	90 grams
Dimensions	72mm x 52mm x 14mm	100mm x 100mm x 28mm
Sensors	Photoplethysmography (PPG) 3D accelerometry (ACC)	
Wireless connection	DECT Ultra Low Energy Indoor range max 15 meters	
Connectivity	Distributed Information System and Distributed Alarm System compatible for professional users	
Certification	MDR (EU) 2017/745 Class IIa	

NightWatch+ is a Class IIa medical device under the EU Medical Device Regulation 2017/745.
Visit our website for product use conditions.

TD-NWP-270 Version: 1.0, April 2025

NightWatch+